Analysis of genetic polymorphism relating to interstitial lung disease events in patients with advanced pancreatic cancer receiving gemcitabine plus erlotinib
Phase of Trial: Phase IV
Latest Information Update: 05 Oct 2018
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Pharmacogenomic
- 03 Oct 2018 Status changed from active, no longer recruiting to completed.
- 01 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan record.
- 05 Oct 2012 New trial record